HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

Eric Van Cutsem, Yung‐Jue Bang, Feng-yi Feng, +13

Gastric Cancer

Repression of p15INK4b expression by Myc through association with Miz-1

Peter Staller, Karen Peukert, Astrid Kiermaier, +8

Nature Cell Biology

Transcriptional RegulationProtein ExpressionMolecular RegulationNatural SciencesMolecular Biology +6

Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer

José Baselga, Javier Cortés, Seock‐Ah Im, +4

Journal of Clinical Oncology

Regulation of <i>cyclin D2</i> gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the <i>cyclin D2</i> promoter

Caroline Bouchard, Oliver Dittrich, Astrid Kiermaier, +4

Genes & Development

Myc-dependent Trrap RecruitmentHistone AcetylationMolecular RegulationGeneticsMolecular Biology +20

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

Stephen J. Luen, Roberto Salgado, Stephen B. Fox, +8

The Lancet Oncology

Breast OncologyMedicineImmunologyCleopatra StudyPathology +6

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

Sandra M. Swain, Michael S. Ewer, Giuseppe Viale, +12

Annals of Oncology

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Giampaolo Bianchini, Astrid Kiermaier, Giulia Bianchi, +12

Breast Cancer Research

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy

Michail Ignatiadis, Gert Van den Eynden, Roberto Salgado, +16

JNCI Journal of the National Cancer Institute

Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study

Andreas Schneeweiß, Stephen Chia, Roberto Hegg, +7

Breast Cancer Research

Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA–Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)

Christian Kurzeder, Isabel Bover, Frederik Marmé, +19

Journal of Clinical Oncology